Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Amarin Reports Year-End and Q4 2010 Results

March 17, 2011 By Bio-Medicine.Org

DUBLIN and MYSTIC, Conn., March 16, 2011 /PRNewswire/ — Amarin
Corporation plc (Nasdaq:
AMRN
), a clinical-stage biopharmaceutical company focused on
cardiovascular disease, today reported financial results for the
fiscal year and fourth quarter ended December 31, 2010. The Company
also provided an update on its progress with the Phase 3
development program of its lead product candidate, AMR101 for the
treatment of elevated triglyceride levels, which are associated
with the increased risk of developing cardiac disease as well as
being a component of certain other metabolic disorders, such as
diabetes and obesity.

As reported by Amarin, key accomplishments since the Company’s
last quarterly financial report of September 30, 2010, include:

Primary endpoints met in Phase 3 MARINE trial with AMR101 at both
4g and 2g doses Strengthened balance sheet with additional $98.7M
cash Completed last patient visit for the Phase 3 ANCHOR trial
Strengthened management team with focus on commercial
–readiness of AMR101 through the addition of an accomplished
Chief Commercial Officer On-track with the existing MARINE trial
data for a New Drug Application (NDA) submission for AMR101 in Q3,
2011

“2010 was a year of great progress for Amarin. We accomplished
our goal of advancing AMR101 toward commercial status with the
release of positive MARINE trial results in the last quarter,”
stated Joseph Zakrzewski, Executive Chairman and Chief Executive
Officer of Amarin.  “Among prescription Omega-3 based drugs,
AMR101 has the potential to be best-in-class for treating patients
with very high triglycerides and the first-in-class for treating
patients with high triglycerides with mixed dyslipidemia. Our focus
is to become the leader in the market for triglyceride-lowering
drugs by providing clinicians and patients a new generation of
prescrip

‘/>”/>

SOURCE

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech